Harmony Biosciences Holdings, Inc. $HRMY Shares Bought by Universal Beteiligungs und Servicegesellschaft mbH

Universal Beteiligungs und Servicegesellschaft mbH lifted its holdings in shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) by 39.3% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 234,779 shares of the company’s stock after buying an additional 66,236 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH owned about 0.41% of Harmony Biosciences worth $6,471,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of the business. Robeco Institutional Asset Management B.V. acquired a new stake in Harmony Biosciences in the second quarter valued at $1,478,000. Capital Fund Management S.A. acquired a new position in shares of Harmony Biosciences during the 2nd quarter worth $1,142,000. Exchange Traded Concepts LLC increased its holdings in shares of Harmony Biosciences by 102.6% in the 3rd quarter. Exchange Traded Concepts LLC now owns 65,023 shares of the company’s stock valued at $1,792,000 after purchasing an additional 32,923 shares in the last quarter. Nomura Holdings Inc. lifted its stake in shares of Harmony Biosciences by 382.3% in the second quarter. Nomura Holdings Inc. now owns 422,919 shares of the company’s stock valued at $13,364,000 after purchasing an additional 335,237 shares during the period. Finally, Arrowstreet Capital Limited Partnership boosted its holdings in Harmony Biosciences by 127.6% during the second quarter. Arrowstreet Capital Limited Partnership now owns 906,909 shares of the company’s stock worth $28,658,000 after buying an additional 508,498 shares in the last quarter. 86.23% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Harmony Biosciences

In other Harmony Biosciences news, CEO Jeffrey M. Dayno sold 25,933 shares of the firm’s stock in a transaction dated Friday, December 12th. The stock was sold at an average price of $40.11, for a total value of $1,040,172.63. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Sandip Kapadia sold 20,961 shares of Harmony Biosciences stock in a transaction dated Thursday, January 15th. The shares were sold at an average price of $35.92, for a total value of $752,919.12. Additional details regarding this sale are available in the official SEC disclosure. 23.60% of the stock is owned by company insiders.

Harmony Biosciences Price Performance

NASDAQ:HRMY opened at $37.36 on Tuesday. Harmony Biosciences Holdings, Inc. has a 12-month low of $25.52 and a 12-month high of $40.87. The firm has a market cap of $2.15 billion, a price-to-earnings ratio of 11.75, a price-to-earnings-growth ratio of 0.34 and a beta of 0.84. The company’s 50-day moving average is $37.15 and its two-hundred day moving average is $34.19. The company has a current ratio of 3.75, a quick ratio of 3.72 and a debt-to-equity ratio of 0.18.

Harmony Biosciences (NASDAQ:HRMY) last issued its quarterly earnings results on Tuesday, November 4th. The company reported $0.87 EPS for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.05). The firm had revenue of $239.46 million for the quarter, compared to analysts’ expectations of $222.68 million. Harmony Biosciences had a return on equity of 24.88% and a net margin of 22.50%. Research analysts expect that Harmony Biosciences Holdings, Inc. will post 2.43 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts have issued reports on HRMY shares. Wall Street Zen raised shares of Harmony Biosciences from a “hold” rating to a “buy” rating in a report on Saturday, December 13th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Harmony Biosciences in a research note on Monday, December 29th. Zacks Research upgraded Harmony Biosciences from a “hold” rating to a “strong-buy” rating in a research report on Thursday, January 22nd. HC Wainwright reissued a “buy” rating on shares of Harmony Biosciences in a report on Wednesday, December 3rd. Finally, Mizuho lifted their price target on Harmony Biosciences from $39.00 to $46.00 and gave the stock an “outperform” rating in a research note on Monday, December 1st. Two equities research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and two have issued a Hold rating to the company. According to MarketBeat, Harmony Biosciences currently has an average rating of “Buy” and a consensus target price of $45.25.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc is a commercial‐stage biopharmaceutical company focused on developing and delivering therapies for people with rare neurological and endocrine diseases. Founded in 2017 and headquartered in Plymouth Meeting, Pennsylvania, Harmony Biosciences went public in 2020 and trades on the Nasdaq under the ticker HRMY. The company’s mission centers on identifying and advancing medicines that address critical unmet needs in patient populations underserved by existing treatments.

The company’s flagship product is WAKIX (pitolisant), the first and only histamine H3 receptor antagonist/inverse agonist approved by the U.S.